^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PD1-Vaxx

    i
    Other names: PD1-Vaxx, IMU-201, APi2568, IMU 201, IMU201
    Company:
    Imugene
    Drug class:
    PD1 inhibitor
    Related drugs:
    13d
    IMPRINTER: A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Terminated, Imugene Limited | Active, not recruiting --> Terminated; Portfolio prioritization
    Trial termination
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • PD1-Vaxx
    15d
    Neo-POLEM: A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer (clinicaltrials.gov)
    P2, N=44, Recruiting, University of Southampton | Not yet recruiting --> Recruiting
    Enrollment open • MSI-H
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    PD1-Vaxx
    1year
    Neo-POLEM: A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, University of Southampton | Trial completion date: Jun 2028 --> Jan 2029 | Initiation date: Dec 2024 --> May 2025 | Trial primary completion date: Aug 2026 --> Jan 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    PD1-Vaxx
    over1year
    Neo-POLEM: A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, University of Southampton
    New P2 trial
    |
    PD-1 (Programmed cell death 1)
    |
    PD1-Vaxx
    over1year
    IMPRINTER: A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1; Trial completion date: Mar 2026 --> May 2025 | Trial primary completion date: Feb 2026 --> Nov 2024
    Combination therapy • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • PD1-Vaxx
    2years
    IMPRINTER: A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1; Recruiting --> Active, not recruiting | N=88 --> 24
    Combination therapy • Enrollment change • Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • PD1-Vaxx
    almost3years
    IMPRINTER: A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1; N=22 --> 88 | Trial completion date: Jul 2023 --> Mar 2026 | Trial primary completion date: Dec 2022 --> Feb 2026
    Combination therapy • Trial completion date • Trial primary completion date • Enrollment change
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • PD1-Vaxx